

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for October 2023

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Teva Canada Limited	Teva-Sunitinib	Sutent	SUNITINIB MALATE	12.5 mg	capsule	02526204
Teva Canada Limited	Teva-Sunitinib	Sutent	SUNITINIB MALATE	25 mg	capsule	02526212
Teva Canada Limited	Teva-Sunitinib	Sutent	SUNITINIB MALATE	50 mg	capsule	02526220
Glenmark Pharmaceuticals Canada Inc.	GLN-Posaconazole	Posanol	POSACONAZOLE	100 mg	DR tablet	02542021
Jamp Pharma Corporation	Jamp Tretinoin	Vesanoid	TRETINOIN	10 mg	capsule	02520036